82 results
10-Q
2019 Q1
HOTH
Hoth Therapeutics Inc
15 May 19
Quarterly report
4:20pm
Months Ended
March 31,
Operating costs and expenses
Research and development - license acquired
Compensation and related expenses (including stock …
Equity
Balance at December 31, 2017
Stock-based compensation (See note 4)
Stock issued for research and development (See note 4)
Stock issued
UPLOAD
HOTH
Hoth Therapeutics Inc
7 Dec 22
Letter from SEC
12:00am
Results of Operations
Research and Development Expenses, page 45
1. Please disclose … the
costs incurred during each period presented for each of your key
research and
development
8-K
EX-99.1
fcfsq shfo5laz
8 Jan 21
License Covers Novel Molecular Entity Developed by the Walter Reed Army Institute of Research
4:19pm
424B3
apffz
16 Sep 19
Prospectus supplement
5:06pm
424B3
b1nbvzfb3 zv6
25 Oct 19
Prospectus supplement
5:12pm